Scholar Rock (NASDAQ:SRRK) Insider Jing Marantz Sells 5,798 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Jing Marantz sold 5,798 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $44.48, for a total transaction of $257,895.04. Following the completion of the sale, the insider owned 95,687 shares of the company’s stock, valued at approximately $4,256,157.76. This trade represents a 5.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Scholar Rock Stock Performance

Shares of SRRK opened at $46.05 on Thursday. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The firm has a market cap of $4.70 billion, a PE ratio of -14.62 and a beta of 0.63. Scholar Rock Holding Corporation has a 12 month low of $22.71 and a 12 month high of $48.28. The stock has a fifty day moving average price of $43.23 and a 200-day moving average price of $37.16.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter in the prior year, the business earned ($0.66) earnings per share. Equities research analysts predict that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Barclays lifted their target price on shares of Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Citigroup initiated coverage on shares of Scholar Rock in a report on Friday, January 9th. They set a “buy” rating and a $55.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. JPMorgan Chase & Co. boosted their price target on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Friday, November 14th. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $50.14.

Institutional Investors Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ramirez Asset Management Inc. acquired a new position in shares of Scholar Rock in the 3rd quarter valued at about $37,000. Penserra Capital Management LLC purchased a new position in Scholar Rock during the third quarter valued at approximately $56,000. Bessemer Group Inc. lifted its holdings in Scholar Rock by 970.0% in the third quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock valued at $86,000 after acquiring an additional 2,105 shares during the period. Strs Ohio purchased a new stake in Scholar Rock in the 1st quarter worth approximately $77,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Scholar Rock during the 2nd quarter worth approximately $94,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).